Welcome to our dedicated page for Casi Pharmaceuticals news (Ticker: CASI), a resource for investors and traders seeking the latest updates and insights on Casi Pharmaceuticals stock.
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is a clinical-stage biopharmaceutical company whose news flow centers on the development and financing of CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. Company announcements highlight clinical trial progress in immune thrombocytopenia (ITP) and renal allograft antibody-mediated rejection (AMR), as well as regulatory milestones in the United States and China.
Readers of CASI news can follow updates on its Phase 1 and Phase 1/2 studies, including dose-escalation designs, interim safety and efficacy data, and presentations at major medical meetings such as the American Society of Hematology (ASH) Annual Meeting. Press releases describe how CID-103 is being evaluated across multiple dose cohorts, report on platelet response outcomes in ITP, and discuss regulatory clearances such as FDA IND approvals and Chinese CTA approvals for AMR studies.
CASI’s news also covers corporate and capital markets developments, including convertible note financings, at-the-market equity raises, and Nasdaq listing compliance matters. The company has reported receiving a Nasdaq delisting determination related to market value of listed securities, its subsequent appeal, and an extension granted by a Nasdaq Hearings Panel to regain compliance. Governance changes, such as board appointments and the designation of a Non-Executive Chairman, are also detailed in recent releases.
In addition, CASI issues updates on its product portfolio and regulatory environment in China, including the expiration of the Import Drug Registration License for FOLOTYN and the impact on commercialization in that market. For investors and observers, the CASI news feed provides a consolidated view of clinical data releases, regulatory interactions, financing transactions, governance changes, and business updates that shape the company’s progress with CID-103 and related activities.
CASI Pharmaceuticals (Nasdaq: CASI) announced a conference call to discuss its second quarter highlights on August 12, 2021, at 8:00 a.m. ET. The call will provide insights from the Chairman & CEO regarding the company's business updates and future milestones. Investors can join the call using specific dialing options for different regions. CASI focuses on developing innovative therapeutics, particularly in hematology oncology, aiming to expand its market presence in China and globally. More details are available on their official website.
CASI Pharmaceuticals announced the first patient dosing in a Phase 1 clinical trial evaluating CID-103, an innovative anti-CD38 monoclonal antibody for relapsed or refractory multiple myeloma. This study aims to assess CID-103's safety, tolerability, and clinical activity. Preclinical data indicated promising efficacy and favorable safety compared to existing treatments. The Company is optimistic about CID-103's potential to provide significant patient benefits and accelerate its development path.
CASI Pharmaceuticals, a U.S. biopharmaceutical company, announced that Dr. Wei-Wu He will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 9:30 AM (EST). The event will showcase the company’s focus on developing therapeutics in hematology oncology and other unmet medical needs. A webcast will be available on CASI's website in the 'Investors Relations' section, with replays for 30 days post-event. CASI aims to leverage its expertise in China and the U.S. to become a leader in the biopharmaceutical industry.
CASI Pharmaceuticals reported a revenue of $5.7 million from EVOMELA for Q1 2021, up from $3.4 million in Q1 2020, with a projected annual growth exceeding 50%. R&D expenses increased to $5.3 million mainly due to the CID-103 project. General and administrative costs rose to $5.5 million, reflecting expanded operations. The net loss for the quarter widened to $13.7 million, compared to $8.2 million in the previous year. The firm raised $32.5 million in capital to enhance its balance sheet.
CASI Pharmaceuticals (Nasdaq: CASI) announced it will host a conference call on May 13, 2021, at 8:00 a.m. ET to review its first quarter highlights. The call will be led by the company's Chairman & CEO, discussing business updates and upcoming milestones. Interested participants can access the call by dialing the relevant numbers for the U.S., China, or Hong Kong, with a conference ID of 7478587. A replay of the call will also be available. CASI focuses on developing therapeutics for hematology oncology and has a significant presence in the Chinese market.
CASI Pharmaceuticals reported its 2020 financial results, disclosing revenue of $15 million, up from $4.1 million in 2019, primarily driven by the sales of EVOMELA. The company forecasted over 50% revenue growth in 2021. It completed a public offering raising $32.5 million and highlighted in-licensing of a VCP/p97 inhibitor for treatment of hematological malignancies. However, net loss increased to $47.5 million from $45.4 million due to rising R&D and acquisition costs. The company is focused on expanding its U.S. investor base while preparing for regulatory filings in China.
CASI Pharmaceuticals (Nasdaq: CASI) announced a public offering of 15,853,658 shares at $2.05 per share, with an option for underwriters to purchase 2,378,048 additional shares. The offering is anticipated to generate approximately $32.5 million in gross proceeds, which is expected to close around March 26, 2021. Proceeds will primarily fund working capital, enhance their product portfolio, and support general corporate needs. The offering is conducted under a shelf registration statement that was declared effective in December 2020.
CASI Pharmaceuticals has launched an underwritten public offering of its common stock, with a provision for underwriters to purchase an additional 15%. The exact size and terms are uncertain. Proceeds will support working capital and advance its product portfolio, including acquiring new product rights. The offering occurs under a previously effective shelf registration statement. Key underwriters include Oppenheimer & Co., Mizuho Securities USA, and BTIG. Investors are advised to review the preliminary prospectus for comprehensive details.
CASI Pharmaceuticals, Inc. (Nasdaq: CASI) announced a conference call on March 12, 2021, at 8:00 a.m. ET to discuss recent business developments and upcoming milestones. Attendees can dial in using provided numbers for the U.S., China, and Hong Kong, or access the live webcast online. An archived version will be available for one year. CASI is focused on developing pharmaceutical products in the U.S. and China, particularly in hematology oncology. More information on CASI can be found on their website.
Cleave Therapeutics and CASI Pharmaceuticals have signed an exclusive licensing agreement for CB-5339, a novel VCP/p97 inhibitor, aimed at treating hematological malignancies and solid tumors in Greater China. Cleave receives a $5.5 million upfront payment and potential milestone payments totaling $74 million, along with tiered royalties on sales. CB-5339 is currently in Phase 1 clinical trials for AML and myelodysplastic syndrome, and the National Cancer Institute is also evaluating it for solid tumors. This partnership is seen as a strategic move to enhance CB-5339's global development.